Literature DB >> 11271540

Provision of hormonal contraceptives without a mandatory pelvic examination: the first stop demonstration project.

C Harper1, E Balistreri, J Boggess, K Leon, P Darney.   

Abstract

CONTEXT: First Stop, an 18-month demonstration project that operated in 1996-1997, was designed to offer low-income adult women in California hormonal contraceptives without requiring a pelvic examination.
METHODS: An evaluation was undertaken to assess the contraceptives adopted by First Stop clients, compare health risks of these women with risks among women using traditional family planning clinics and assess clients'satisfaction. Data on 2,065 First Stop clients and 1,507 women attending traditional clinics were collected through several self- and clinician-administered instruments, including questionnaires, a telephone survey and medical chart abstractions.
RESULTS: After the initial First Stop visit, 38% of women adopted a more effective method than they had used at last sex, 4 7% remained with the same method, 12% switched to a less-effective method and 3% accepted no method. Of clients who were referred for additional medical care, 73% followed through on their referrals. Compared with clients at traditional clinics, First Stop clients were less likely to have a regular source of health care, but more likely to have made a health care visit in the past year. Most First Stop clients valued the project's services; 76% said it was important to be able to receive pills or injections without a pelvic examination.
CONCLUSIONS: Programs that provide hormonal contraceptives without requiring a pelvic examination can expand low-income women's access to these methods and improve the chances that they will obtain other reproductive health services.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11271540

Source DB:  PubMed          Journal:  Fam Plann Perspect        ISSN: 0014-7354


  8 in total

1.  Pelvic examinations and access to oral hormonal contraception.

Authors:  Jillian T Henderson; George F Sawaya; Maya Blum; Laura Stratton; Cynthia C Harper
Journal:  Obstet Gynecol       Date:  2010-12       Impact factor: 7.661

2.  Recommendations on routine screening pelvic examination: Canadian Task Force on Preventive Health Care adoption of the American College of Physicians guideline.

Authors:  Marcello Tonelli; Sarah Connor Gorber; Ainsley Moore; Brett D Thombs
Journal:  Can Fam Physician       Date:  2016-03       Impact factor: 3.275

3.  Concern is not based on evidence.

Authors:  Ainsley Moore
Journal:  Can Fam Physician       Date:  2016-09       Impact factor: 3.275

4.  Reproductive health preventive screening among clinic vs. over-the-counter oral contraceptive users.

Authors:  Kristine Hopkins; Daniel Grossman; Kari White; Jon Amastae; Joseph E Potter
Journal:  Contraception       Date:  2012-04-20       Impact factor: 3.375

5.  Why Iranian married women use withdrawal instead of oral contraceptives? A qualitative study from Iran.

Authors:  Parvin Rahnama; Alireza Hidarnia; Farkhondeh Amin Shokravi; Anoushiravan Kazemnejad; Deborah Oakley; Ali Montazeri
Journal:  BMC Public Health       Date:  2010-05-28       Impact factor: 3.295

6.  Routine bimanual pelvic examinations: practices and beliefs of US obstetrician-gynecologists.

Authors:  Jillian T Henderson; Cynthia C Harper; Sarah Gutin; Mona Saraiya; Jocelyn Chapman; George F Sawaya
Journal:  Am J Obstet Gynecol       Date:  2012-11-22       Impact factor: 8.661

7.  Kentucky pharmacists' perceptions regarding provision of hormonal contraception.

Authors:  Dustin K Miracle; GYeon Oh; Michael Singleton; Clark D Kebodeaux; Joseph L Fink; Patricia R Freeman
Journal:  J Am Pharm Assoc (2003)       Date:  2021-07-21

8.  Delayed Visits for Contraception Due to Concerns Regarding Pelvic Examination Among Women with History of Intimate Partner Violence.

Authors:  Hunter K Holt; George F Sawaya; Alison M El Ayadi; Jillian T Henderson; Corinne H Rocca; Carolyn L Westhoff; Cynthia C Harper
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 6.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.